← Leaderboards
Melissa L Fishel
Indiana Univ-Purdue Univ At Indianapolis
$7,092,542
Attributed
$17,208,751
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,208,751 · 6
By mechanism
R01$8,927,206 · 3
U01$7,948,245 · 2
R21$333,300 · 1
Top collaborators
- Mark R. Kelley17 shared
- Bumsoo Han15 shared
- Matthew J. Flick10 shared
- Alisa S Wolberg5 shared
Most similar at Indiana Univ-Purdue Univ At Indianapolis
Same institution · by research overlap
- Mark R. Kelley$16,203,613
- Lang Li$13,579,025
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant Neoplasm Of PancreasTumor GrowthPancreatic Ductal AdenocarcinomaSignal TransductionMalignant NeoplasmsIn VivoGrowthMolecular TargetFibroblastsTumor MicroenvironmentCellsPathway InteractionsOxidation-ReductionTranscription FactorResistanceEvaluationCoculture TechniquesCritical PathwaysSurvival Rate3-DimensionalSignal PathwayCancer EtiologyPharmaceutical Preparations
Grant awards (34)
Reprogramming PDAC Stroma by Targeting Coagulation in the Tumor Microenvironment$932,376
U01 · FY2025 · CA
Metabolic flux analysis and PDX models to understand therapeutic vulnerabilities following inhibition of Ref-1 redox signaling in pancreatic cancer$479,470
R01 · FY2025 · CA
Investigation of novel signaling protein in 3D and in vivo PDAC models using second generation Ref-1 inhibitors$433,463
R01 · FY2025 · CA · contact PI
Metabolic flux analysis and PDX models to understand therapeutic vulnerabilities following inhibition of Ref-1 redox signaling in pancreatic cancer$81,710
R01 · FY2025 · CA
Reprogramming PDAC Stroma by Targeting Coagulation in the Tumor Microenvironment$885,794
U01 · FY2024 · CA
Metabolic flux analysis and PDX models to understand therapeutic vulnerabilities following inhibition of Ref-1 redox signaling in pancreatic cancer$443,001
R01 · FY2024 · CA
Investigation of novel signaling protein in 3D and in vivo PDAC models using second generation Ref-1 inhibitors$411,790
R01 · FY2024 · CA · contact PI
Metabolic flux analysis and PDX models to understand therapeutic vulnerabilities following inhibition of Ref-1 redox signaling in pancreatic cancer$75,358
R01 · FY2024 · CA
Metabolic flux analysis and PDX models to understand therapeutic vulnerabilities following inhibition of Ref-1 redox signaling in pancreatic cancer$27,108
R01 · FY2024 · CA
Reprogramming PDAC Stroma by Targeting Coagulation in the Tumor Microenvironment$670,662
U01 · FY2023 · CA
Metabolic flux analysis and PDX models to understand therapeutic vulnerabilities following inhibition of Ref-1 redox signaling in pancreatic cancer$466,315
R01 · FY2023 · CA
Investigation of novel signaling protein in 3D and in vivo PDAC models using second generation Ref-1 inhibitors$424,794
R01 · FY2023 · CA · contact PI
Reprogramming PDAC Stroma by Targeting Coagulation in the Tumor Microenvironment$257,378
U01 · FY2023 · CA
Reprogramming PDAC Stroma by Targeting Coagulation in the Tumor Microenvironment$956,721
U01 · FY2022 · CA
Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis$834,158
U01 · FY2022 · HL
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations$483,852
R01 · FY2022 · CA
Investigation of novel signaling protein in 3D and in vivo PDAC models using second generation Ref-1 inhibitors$424,794
R01 · FY2022 · CA · contact PI
Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis$844,766
U01 · FY2021 · HL
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations$493,726
R01 · FY2021 · CA
Investigation of novel signaling protein in 3D and in vivo PDAC models using second generation Ref-1 inhibitors$448,088
R01 · FY2021 · CA · contact PI
Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis$855,078
U01 · FY2020 · HL
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations$493,726
R01 · FY2020 · CA
Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis$892,860
U01 · FY2019 · HL
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations$563,735
R01 · FY2019 · CA
Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis$818,452
U01 · FY2018 · HL
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations$493,726
R01 · FY2018 · CA
Exploiting the Ref-1 node in pancreatic cancer: tailoring new pancreatic cancer therapy using multi-targeted combinations$227,554
R01 · FY2018 · CA
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression$493,963
R01 · FY2017 · CA
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression$493,963
R01 · FY2016 · CA
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression$493,963
R01 · FY2015 · CA
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression$479,144
R01 · FY2014 · CA
Novel Role of Ref-1 in Pancreatic Cancer Etiology and Progression$493,963
R01 · FY2013 · CA
Chemosensitization of Pancreatic Tumors via Inhibition of a DNA BER Enzyme, Ape1$181,800
R21 · FY2008 · CA · contact PI
Chemosensitization of Pancreatic Tumors via Inhibition of a DNA BER Enzyme, Ape1$151,500
R21 · FY2007 · CA · contact PI